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The themes in this session on health care utilization explored issues related to the cost of health care and 
prescription drug use.  These studies are typically conducted using secondary data sources, such as claims data 
or population survey data.  Foster and Polgreen applied time series analysis to examine seasonal variation in 
heart failure, while Zhao and Carlson reported trends in self-reported blood glucose control and use of 
antihyperglycemics.  The Nationwide Re-admission Database (NRD) was used by Chen et al to determine whether 
readmission rates differed by insurance status among patients who underwent breast cancer surgery.  Zhou and 
Calip examined the cost of an innovative therapy by comparing allogenic hematiopoietic stem cells 
transplantation versus hydroxyurea therapy in children with sickle cell disease.  In addition to examining patterns 
of medication use and comparing the costs or effectiveness of treatments, secondary data also can be used to 
evaluate the impact of pharmaceutical policy.  This was the focus of the investigation by Sharma and colleagues 
of the FDA’s unapproved drug initiative (UDI) on drug prices and expenditures which generated some remarkable 
results on the subsequent prices of generic drugs.  In the spirit of the meeting, proposed studies yet to be 
conducted were also presented, including Sajan Pandya’s examining of patients initiating therapies with DPP-4 
inhibitors and GLP-1 agonists using the Medical Expeditures Panel Survey (MEPS).  Alternatively, systematic 
reviews of the literature can be used to conduct studies such as meta-analyses to compare the effectiveness of 
treatment, as was done by Kumar et al in their comparison of fondaparinux to low molecular weight heparins for 
thrombopropylaxis.  The presentations in this session demonstrated the ongoing importance using established 
methodologies and secondary data to understand patterns of use of medications and to compare the clinical and 
economic outcomes drug treatments to better inform medical decision making.  It also highlighted the need for 
additional information to inform patient centered care, such as patient preferences for treatment, that should 
supplement information about clinical outcomes and costs of treatment, particularly when there are tradeoffs 
to be made between clinical and economic outcomes.                   
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ABSTRACT 
Objective: To compare the real-world cost-effectiveness of hematopoietic stem cells transplantation (HSCT) and Hydroxyurea 
(HU) in a commercially-insured U.S. population of sickle cell disease (SCD) patients aged ≤17 years. The primary outcomes 
were all-cause per person per month costs and all-cause acute care encounters defined as inpatient admissions and 
emergency room (ER) visits. 
 
Methods: We conducted a population-based cohort study using the Truven Health MarketScan® Research databases (2009-
2014). Pediatric patients with SCD undergoing allogeneic HSCT and those newly initiating HU (index date: stem cell infusion 
and prescription dispensing, respectively) with continuous health plan enrollment for ≥6 months before and after the index 
date were included.  
 
Results: We identified 16 HSCT recipients and 400 pediatric HU initiators. The mean (SD) age at cohort entry were 8.8 (4.6) 
and 10.0 (4.6) years among pediatric and adolescent patients with SCD. Prior to the index date, HSCT recipients had greater 
occurrence of iron overload (37.5% vs. 7.8%; p<0.0001) and stroke (12.5% vs. 2.5%; p=0.0191). Over a median follow-up of 
27 and 22 months post-transplantation and HU initiation, the mean (SD) all-cause per person per month (PPPM) acute care 
utilization were similar (0.21 (0.36) vs. 0.21 (0.26), p = 0.9641). HSCT recipients had significantly lower mean (SD) PPPM SCD-
related acute care utilization (0.02 (0.03) vs. 0.12 (0.19), p < 0.0001); despite higher mean (SD) PPPM health costs ($19,062 
(14,600) vs. $2,485 (3,492), in 2014 U.S. dollars; p=0.0004). Only modest differences in all-cause health expenditures persisted 
beyond the first year post-treatment (mean (SD), $3,593 (5,565) vs. $2,783 (5,031); p=0.5590). 
 
Conclusion: We found lower SCD-related acute care utilization following HSCT and similar all-cause health expenditures 
relative to HU therapy following one year post-transplantation among pediatric patients with SCD. 
 
 
Key words: Cost-effectiveness analysis, Sickle cell disease, Hematopoietic stem cells transplantation, Hydroxyurea 
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ABSTRACT 
Objectives: The objective of this meta-analysis was to systematically review the randomized clinical trials (RCTs) of 
Fondaparinux Sodium once daily versus low molecular weight heparins (LMWH) at the titrated dose for the prophylaxis of 
venous thromboembolism (VTE) among the patients with orthopedic immobility.  
 
Methods: Systematic search in the database e.g. EMBASE, MEDLINE, Cochrane Library, ProQuest, Science Direct, Google 
Scholar and clinicaltrials.gov was done to identify RCTs evaluating both treatments for the prophylaxis of VTE published in 
English language from the year 2000 to 2017. A web-based systematic review tool “Covidence” was used to systematically 
screen the studies of interest. Analysis in “RevMan” was performed with the relative odds based on the fixed and random 
effect models. Results were presented as odds ratios (OR) with their 95% confidence intervals. The assessment of study 
quality and risk of bias among the included studies was performed as per Cochrane collaboration.  
 
Results: After screening 10,644 articles, 4,721 were selected for review. Nine RCTs were included in the final analysis. 
Pooled analyses showed a significant 58% reduction for VTE (OR=0.42 [0.32, 0.56]) and 5% reduction in mortality (OR=0.95 
[0.64, 1.40]) with Fondaparinux Sodium compared to LMWH. Contrarily, there was a significant 55% increase in the risk for 
major bleeding (OR=1.55 [1.15, 2.10]) and 15% increase in minor bleeding (OR=1.16 [0.90, 1.50]) with Fondaparinux Sodium 
compared to LMWH. Quality assessment results identified three of the nine studies at high risk for bias due to “Blinding of 
Participants and Personnel”. 
 
Conclusions: This meta-analysis concluded that Fondaparinux Sodium was superior to LMWH in reduction of VTE and 
mortality but increased the risk for major bleeding. Pharmacists should be aware of potential adverse effects from 
administering Fondaparinux Sodium with orthopedic immobility. 
 
 
Keywords: Fondaparinux Sodium. Low Molecular Weight Heparins, Venous thromboembolismKey words: Cost-
effectiveness analysis, Sickle cell disease, Hematopoietic stem cells transplantation, Hydroxyurea 
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ABSTRACT 
Introduction: Previous studies have found racial and socio-economic disparities in breast cancer hospitalization outcomes. 
However, whether readmission outcomes following the hospitalization differ by primary insurance is largely unknown.  
Objective: To examine whether 30-day all-cause readmissions differ by primary insurance among patients who underwent 
breast cancer surgeries. 
Methods: A retrospective observational study using Nationwide Readmission Database (NRD) were conducted to identify 
patients (aged ≥ 40 yrs) undergoing breast cancer surgeries in 2015. Our outcome of interest was 30-day risk-standardized 
all-cause readmission. Outcomes were estimated and stratified by primary insurance. Hierarchical logistic regression models 
accounting for hospital clustering were performed to examine predictors of readmission. Additional analysis using risk 
adjustment and reliability adjustment were conducted to assess hospital variability in readmission metric.   
Results: Of 5,150 patients undergoing breast cancer surgeries at 1,103 hospital sites, 277 (5.4%) patients were reamitted 
within 30 days. Diabetes [aOR: 1.74 (1.22-2.50)], COPD [aOR: 1.47 (1.02-2.13)] and higher risk of mortality [aOR: 1.69 (1.13-
2.51) moderate vs mild; 3.87(2.16-6.93) major & extreme vs mild] were significant predictors for readmissions. In subgroup 
analysis, an increased risk of readmission was associated with large hospital bedsize in the private-insured group [aOR: 2.11 
(1.01-4.42) vs small], however, none of the hospital characteristics had a significant effect on readmissions in the Medicare 
& Medicaid group. Risk-adjusted readmission rates varied widely across overall hospitals [ICC: 10.63%]; wider variation 
existed in subgroup analysis [ICC: 17.97% (Medicare & Medicaid) vs 21.11% (private insurance)]. Mean risk-standardized 
hospital-wide readmission rates [Mean: 6.22 (SD: 2.01)] were higher for Medicare & Medicaid patients compared to the 
private-insured [Mean: 4.86 (SD: 1.43)]. Of 523 hospitals having patients with both insurance, 465 (88.9%) hospitals presented 
higher readmission rates for Medicare & Medicaid patients, that were more likely to be large (50.8%), private invest-owned 
(16.3%), teaching (55.1%) hospitals with large operative volume (82.4%) of the breast cancer surgeries.  
Conclusion: Using a national sample of hospitalized patients with breast cancer surgeries, differences in readmission metrics 
by primary insurance existed. Lower hospital readmission rates but higher variation was observed among private-insured 
patients compared to Medicare & Medicaid patients. These findings suggest that higher readmission rates may be a quality 
metric for lower hospital care where hospitalized private-insured patients received the treatments following the breast 
cancer surgeries. 
 
*** Abbreviation: aOR = adjusted odds ratio; ICC = intracluster correlation coefficient *** 
 
Keywords: breast cancer surgeries; readmission; insurance; risk adjustment; quality of care  
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ABSTRACT 
Introduction: Heart Failure (HF) is a significant cause of morbidity and mortality in the United States.  One of the main risk 
factors for HF is a previous acute myocardial infarction (AMI).  It has been shown that AMIs are seasonal with higher rates 
occurring in winter months.  Since there is a seasonal pattern to AMIs, there was interest in determining if HF 
hospitalization rates may also have a seasonal pattern.   
 
Methods: Using the National Inpatient Sample database during the years 1998-2011, we identified all hospitalizations with 
primary CCS codes for HF for patients who were 18 years of age or older.  To estimate monthly incidence, we aggregated by 
year and month and applied appropriate weights.  We fit a collection of time series models to determine the trend and 
seasonality of HF hospitalizations to determine how it varies across regions within the US.   
 
Results: There were 13,284,216 hospitalizations due to HF during the study period.  Our model suggests that the risk for 
hospitalization due to HF is seasonal with the peak months being winter months.  The highest risk month was February, 
while the lowest risk month was August.  The seasonality was consistent across the census bureau-designated regions.   
 
Conclusion: As we expected, HF hospitalizations are seasonal with the peak months being during winter.  These results 
indicate the importance of management of HF.  The specific reason that HF exhibits a seasonal pattern is unknown.  
Therefore, more information regarding environmental risk factors may lead to better prevention of hospitalizations, which 
can significantly reduce HF cost in the United States.   
 
 
Key Words: Heart Failure, Seasonality, Time Series, Trends 
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ABSTRACT 
Introduction: Among people 18 years or older the prevalence of diabetes in the United States in 2015 was approximately 
30.2 million people, or 12.2%. This study examines the association between glycohemoglobin (HbA1c) levels and reported 
use of antidiabetic medications for persons with a diagnosis of diabetes. 
Methods: The 2013-2014 National Health and Nutrition Examination Survey (NHANES) was used for analysis. Persons were 
identified based on response to a health survey question regarding diagnosis of diabetes by a health care professional. HbA1c 
values were provided in the lab data file; antidiabetic medications were identified using generic drug name available in the 
prescription medication data file. Chi square test compared differences in antidiabetic medication utilization by HbA1c level 
group (<=7% vs >7%).  P value<0.05 was considered statistically significant.  
Results: Among US adults (>=20 years old) there were 707 who reported a diagnosis of diabetes and included in analysis. This 
corresponds to a weighted prevalence of 10.1% (95% CI: 9.0–11.1). About 48% were aged 45-64 years old; 51% were female. 
The proportion with HbA1c >7% was 46%.  Overall, 83.3% reported use of antidiabetic medications; 13.5% with both insulin 
and oral antidiabetic agents, 14.8% insulin only; 55% oral antidiabetic agents only. The proportion of patients reporting any 
use of insulin was significantly higher among persons with HbA1c >7% than among those with HbA1c <=7% (45% vs 15%, 
respectively; p <.0001). Reported use of oral antidiabetic agents only was significantly higher among patients with HbA1c 
<=7% (62% vs 47%; p <.0001). Among persons using oral antidiabetic medications, use of sulfonylureas was significantly higher 
among patients with HbA1c >7% (33% vs 18%; p <.0001).  
Conclusions: About 46% of US adults reporting diabetes did not achieve an HbAIc target suggesting glycemic control. 
Healthcare professionals might identify more effective treatments or diabetes care managements to control glucose level in 
these patients. 
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ABSTRACT 
Introduction. According to Center for Disease Control, 30.3 million people (approximately 9.4%) of the US population has 
diabetes with prevalence only set to increase. Metformin is the preferred pharmacologic choice in the management of type 
2 diabetes mellitus (T2DM). However, if glucose level is uncontrolled with metformin, a second agent is added. The choice 
for the second agent includes dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. 
Although there have been studies associated with clinical outcomes of DPP-4 inhibitors and GLP-1 agonists, there have been 
limited studies describing healthcare utilization associated with initiating these therapies.  
Objectives: The objective of this study is to examine healthcare utilization of T2DM patients initiating therapies with DPP-4 
inhibitors and GLP-1 agonists using the Medical Expenditure Panel Survey (MEPS). 
Theoretical Framework: Andersen healthcare utilization model will be used in this study. According to the model, use of 
health services is determined by: predisposing factors, enabling factors, and need. In this study, predisposing factors such as 
age and race and enabling factors such as access to and type of health insurance will be examined.  
Proposed Methods: This study will use MEPS panel 19 longitudinal data file and household component events file from 2014 
and 2015. Patients with T2DM will be identified from medical conditions file using ICD-9 code of 250. Patients on DPP-4 
inhibitors and GLP-1 agonists will be identified from prescribed medicines file. Then to filter patients initiating therapy with 
DPP-4 inhibitors or GLP-1 agonists, variables RXBEGMM and RXBEGYRX will be used. All patients initiating therapy between 
January 1, 2014 to December 31, 2015 and continuing therapy for at least 6 months will be included in the study. Healthcare 
utilization for six months after initiating therapy will be examined.  
 
Key Words: Healthcare utilization, Type 2 diabetes, DPP-4 inhibitors, GLP-1 agonists, MEPS 
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ABSTRACT 
Introduction: The 2006 FDA-UDI was implemented to help remove unsafe/ ineffective drugs. Manufacturers of such drugs 
could conduct studies to prove safety and/or efficacy and file a New Drug Application, for which approval provided limited 
market exclusivity. To date, very few studies have examined consequences of this policy on post-approval prices and 
quantities sold.  
Objective: Measure the impact on prices, expenditures, quantities sold, and price elasticities for drugs approved under the 
FDA-UDI. 
Methods: The DESI-II list prepared by the FDA Prescription Drug Wrap-Up program of 1984 was systematically searched to 
identify single-entity unapproved marketed prescription drugs. For the drugs which obtained voluntary FDA approval within 
the FDA-UDI from 2006-2015, a retrospective analysis was conducted using IQVIA National Sales Perspective database to 
analyze trends in total expenditures, units sold, price/unit and price elasticities. All prices were adjusted to 2017 dollars.  
Results: Seventeen previously-marketed unapproved drug products were identified and 12 were included in the analysis (five 
excluded due to missing data). Compared to two years before approval, a steep increase in price and expenditures was 
observed two years post-approval for all except one with mean and median absolute percentage change of 1,684% (SD: 
3,358%) and 275% (Range: +10,729% to -46%) for price and 1,167% (SD: 2.072%) and 343% (Range: -14% to 6,679%) for 
expenditure. Substantial variance was observed in the changes in units sold. The demand for all except two products was 
found to be price inelastic. 
Conclusion and Implication: A marked increase was seen in post-approval prices and expenditures for the vast majority of 
drugs approved in the FDA-UDI with highly variable corresponding changes in units sold. As the FDA-UDI is still ongoing, 
consideration of the impact on post-approval drug prices should be given along with added assurances of safety and efficacy 
of these drug products and reform should be considered.  
 
